Biochemical Failure
Fig. 1 – · Panel A
Panel A 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Krishnan R Patel, Paul L Nguyen, James A Proudfoot, Yang Liu, Alan Dal Pra, Daniel E Spratt, Alan Pollack, Howard M Sandler, Jason A Efstathiou, Colleen Lawton, Jeffry P Simko, Seth A Rosenthal, Kenneth L Zeitzer, Lucas C Mendez, Alan C Hartford, William A Hall, Anand B Desai, Stephanie L Pugh, Elai Davicioni, Phuoc T Tran, Felix Y Feng
Eur Urol Oncol 9(2) 413-421
BACKGROUND AND OBJECTIVE: Long-term (LT) androgen deprivation therapy (ADT) has been found to be beneficial to patients with high-risk prostate cancer (PCa). However, administration of LT-ADT to all patients with high-risk PCa may lead to overtreatment. Enhanced risk stratification using genomic classifiers (such as the recently developed prostate subtyping classifier [PSC]) might be useful. This study aims to characterize the prognostic and predictive ability of the PSC in patients with high-risk PCa undergoing radiotherapy long-term (LT; 24-28 mo) versus short-term (ST; 4 mo) ADT. METHODS: Biopsy samples from three randomized, phase 3 trials-NRG/RTOG 9202, 9413, and 9902-were classified as either PSC basal or luminal. The prognostic and predictive values of PSC for each oncologic endpoint (biochemical failure [BF], distant metastasis [DM], metastasis-free survival [MFS], PCa-specific mortality [PCSM], overall survival [OS]) and other cause-mortality (OCM) were assessed with Cox proportional hazards (MFS, OCM, and OS), Fine-Gray (BF, DM, and PCSM), and restricted mean survival time (RMST) models. KEY FINDINGS AND LIMITATIONS: On a multivariable analysis, the basal subtype was found to have a worse prognosis for MFS (hazard ratio [HR] 1.8 [1.3-2.5], p < 0.001), PCSM (subdistribution HR 2.4 [95% confidence interval {CI} 1.4-4.1], p = 0.001), and OS (HR 1.8 [1.3-2.6], p < 0.001). Ten-year PCSM was 15% better for the luminal subtype than for the basal subtype (11% [95% CI 6-15%] vs 26% [95% CI 17-35%]). A significant interaction between ADT duration (LT vs ST) and PSC subtype (basal vs luminal) was observed for PCSM (pinteraction = 0.008), leading to the observation that 10-yr PCSM was improved with LT-ADT only in patients with basal-type tumors (5% [95% CI 0-11%] vs 42% [29-56%], p < 0.001). Improvements in 10-yr RMST with LT-ADT were greater for basal tumors for oncologic endpoints with the exception of OCM. CONCLUSIONS AND CLINICAL IMPLICATIONS: PSC is both a prognostic and a predictive biomarker for patients who benefit from LT-ADT. PSC subtypes may be used to personalize ADT recommendations for patients with high-risk PCa, pending further validation in a prospective study. PATIENT SUMMARY: In this study, we tried to understand the usefulness of a new genomic test in patients with high-risk, nonmetastatic prostate cancer who underwent radiation therapy and hormonal therapy (HT). We found that this test can help determine a patient's prognosis (eg, a patient's chance of having the cancer return) and, more importantly, personalize treatment decisions by understanding which patients may benefit from long-term HT. This has the potential to save many patients who may not benefit from prolonged HT from "overtreatment" or the unnecessary side effects of such treatment.
2 个 Figure · 8 个 KM 面板
Fig. 1 – Cumulative incidence and survival plots by prostate subtyping classifier (PSC) subtype for six prostate cancer endpoints. Here, outcomes after treatment by binary PSC subtype categorization (basal subtype [basal immune or basal neuroendocrine] vs luminal subtype [luminal differentiated or luminal proliferating]) are shown for (A) biochemical failure, (B) distant metastases (DMs), (C) metastasis-free survival (MFS), (D) prostate cancer–specific mortality (PCSM), (E) other-cause mortality (OCM), and (F) overall survival (OS). The plots represent the cumulative incidence for endpoints where death serves as a competing risk (BF, DM, PCSM, and OCM) and Kaplan-Meier estimated survival for other endpoints (MFS and OS). BF = biochemical failure; CI = confidence interval; HR = hazard ratio; sHR = subdistributional hazard ratio.
Fig. 1 – · Panel A
Panel A 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 – · Panel B
Panel B 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 – · Panel C
Panel C 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 – · Panel D
Panel D 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 – · Panel E
Panel E 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 1 – · Panel F
Panel F 是同一 Fig. 1 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 – (A) Cumulative incidence of prostate cancer–specific mortality (PCSM) by duration of androgen deprivation therapy (long-term [≥24 mo] vs short-term [4 mo] ADT) and prostate subtyping classifier (PSC) category (basal or luminal), with adjusted subdistributional hazard ratios (sHRs) and their 95% confidence intervals (CIs) estimated from multivariable Fine and Gray interaction models. (B) Differences in restricted mean survival times (in months with corresponding 95% CIs) by duration of ADT (long term [≥24 mo] vs short term [ < 4 mo]) for basal and luminal subtypes for all endpoints at 5-, 10-, and 15-yr follow-up. Note that basal subtype did not have 15-yr follow-up for the biochemical failure endpoint. ADT = androgen deprivation therapy; CI = confidence interval; ΔRMST = difference in restricted mean survival time; sHR = subdistributional hazard ratio.
Fig. 2 – · Panel Luminal_Subtypes
Panel Luminal_Subtypes 是同一 Fig. 2 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 2 – · Panel Basal_Subtypes
Panel Basal_Subtypes 是同一 Fig. 2 – 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。